Mirum Pharmaceuticals, Inc.

MIRM

$101.14

+0.50%

2026-09-04 12:38:56 EDT+$0.51

Healthcare

Biotechnology

NASDAQ

Active Trading

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead ...

Price Action of MIRM

$101.14

+0.50%+$0.51

High—

Low—

52W High-22.2%

Rel. vol—

Interval

Range3.1h

Volume—SMA5SMA10

—

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical company dedicated to advancing treatments for rare and orphan diseases, with a primary focus on liver and related metabolic disorders. Founded in 2018 in Foster City, California, Mirum has rapidly grown into a leading rare disease company with a global footprint. The ...Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical company dedicated to advancing treatments for rare and orphan diseases, with a primary focus on liver and related metabolic disorders. Founded in 2018 in Foster City, California, Mirum has rapidly grown into a leading rare disease company with a global footprint. The company's mission is to develop patient-inspired therapies where unmet medical need is greatest. Mirum's lead product, LIVMARLI (maralixibat), is an oral ileal bile acid transporter (IBAT) inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC). LIVMARLI is also being investigated for biliary atresia, a serious pediatric liver disease. The company's pipeline includes Volixibat, another IBAT inhibitor in Phase 2 trials for intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis, as well as other early-stage candidates. Mirum has established a broad commercial presence, with approvals in multiple countries and partnerships to expand global access. Financially, the company has shown strong revenue growth, driven by LIVMARLI sales, though it continues to incur net losses due to significant R&D and commercialization expenses. As of 2026, Mirum reported approximately 392 employees, reflecting its expansion. Key personnel include CEO and co-founder Christopher Peetz, who brings extensive experience in biopharmaceutical finance and leadership. Other members of the leadership team include Jean-Luc Girardet, Chief Technical Officer, and Alejandro Dorenbaum, a co-founder with expertise in drug development. Mirum is committed to corporate responsibility and patient advocacy, participating in initiatives like the Fragile X Conference and other rare disease communities. The company's strategy focuses on rescuing overlooked rare disease programs and advancing them through development and commercialization, with a goal of becoming a leader in rare liver disease therapeutics.ExpandCollapse

Founded

2018

Employees

433

CEO

Christopher Peetz

Full Name

Mirum Pharmaceuticals, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-410.20%

Market Cap

$6.17B

Current Ratio

2.86

WACC

6.77%

ROIC

-119.26%

Contact Information

https://www.mirumpharma.com

650 667 4085

989 East Hillsdale Boulevard, Foster City, CA 94404

Key Metrics of MIRM

Snapshot

Latest / TTM · 6 periods

Market Cap

$6.17B

ROCE

-13.1%

EV / EBITDA

-8.45x

-9.6% YoY

FCF Yield

-7.5%

-8.9% YoY

Cash Conversion Cycle

93.4d

Current Ratio

2.86

Quick take

TTM —

Positive CCC

Financial Highlights of MIRM

Profitability trend

Latest / TTM · 6 periods

Gross Margin

81.7%

Net Margin

-139.2%

P/E Ratio

-6.91x

n/a

Debt / Equity

-72.97

n/a

Current Ratio

2.86

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of MIRM

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.53 · Revenue $178.06M · 3 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.62 · Revenue $183.81M · 4 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-15.13 · Revenue $697.93M · 7 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.33 · Revenue $189.50M · 1 analysts

Recent history

Aug 5, 2026
Q2 FY2026 · Results reported
EPS $-1.06 · Revenue $176.24M
View filing
May 6, 2026
Q1 FY2026 · Results reported
EPS $-13.43 · Revenue $159.88M
View filing
Feb 25, 2026
FY2025 · Annual results
EPS $-0.47 · Revenue $521.31M
View filing
Nov 4, 2025
Q3 FY2025 · Results reported
EPS $0.05 · Revenue $133.01M
View filing
Aug 6, 2025
Q2 FY2025 · Results reported
EPS $-0.12 · Revenue $127.78M
View filing
May 7, 2025
Q1 FY2025 · Results reported
EPS $-0.30 · Revenue $111.58M
View filing

Financial Statements of MIRM

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$521.3M	+54.7%	+10.2%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-23.4M	+73.4%	+91.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+80.7%	+6.5%	+1.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-4.2%	+83.7%	+38.9%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-4.5%	+82.8%	+92.3%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$54.9M	+488.0%	-19.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+10.5%	+280.0%	-8.2%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	101.5%	-27.9%	-5565.4%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	2.67x	-13.9%	+36.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$842.8M	+25.7%	+17.3%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.47 vs -0.25	-90.8%	-1.06 vs -0.74	-42.8%
Revenue Surprise	$521.3M vs $515.5M	+1.1%	$176.2M vs $166.3M	+6.0%

Insider Transactions of MIRM

Acquisitions (A)

Since Aug 10, 2026

Disposals (D)

Since Aug 10, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Sep 2, 2026	Howe Jolanda	officer: SVP, GLOBAL CONTROLLER	Common Stock	D	658	$100.00
Sep 1, 2026	Peetz Christopher	director, officer: CHIEF EXECUTIVE OFFICER	Common Stock	A	30,000	$2.94
Sep 1, 2026	Peetz Christopher	director, officer: CHIEF EXECUTIVE OFFICER	Common Stock	D	8,312	$98.08
Sep 1, 2026	Peetz Christopher	director, officer: CHIEF EXECUTIVE OFFICER	Common Stock	D	21,688	$98.91
Sep 1, 2026	Peetz Christopher	director, officer: CHIEF EXECUTIVE OFFICER	Employee Stock Option (right to buy)	D	30,000	$2.94

Earnings Call Transcript of MIRM

3 transcript segments

Q2 2026

OperatorOperatorSentiment 0.0

Good afternoon, and welcome to Mirum Pharmaceuticals Second Quarter of 2026 Earnings Conference Call. My name is Alexandra, and I will be your operator today. All lines are currently in a listen-only mode. There will be an opportunity for Q&A after management's prepared remarks. I would now like to hand the conference over to Andrew McKibben, SVP of Strategic Finance and Investor Relations. Please go ahead.

Andrew McKibbenSVP, Strategic Finance and Investor RelationsSentiment 0.0

Thank you, Alexandra, and good afternoon, everyone. I would like to welcome you to Mirum Pharmaceuticals' second quarter of 2026 conference call. I am joined today by our Chief Executive Officer, Christopher Peetz; our President and Chief Operating Officer, Peter Radovich; and Eric H. Bjerkholt, our Chief Financial Officer. Lara Longpre, our Chief Development Officer, will be joining us for the Q&A portion of the call. Joanne Quan, our Chief Medical Officer, could not be with us today due to a family matter. Earlier today, Mirum issued a press release announcing the company's results for the second quarter of 2026. Copies of the press release and our SEC filings are available on the Investors section of our website. Before we start, I would like to remind you that during the course of this conference call, we will be making certain forward-looking statements based on management's current expectations, including statements regarding Mirum's programs and market opportunities for its approved medicines and product candidates and financial guidance. These statements represent our judgment and knowledge of events as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. We are under no duty to update these statements. Please refer to the risk factors in our latest Form 10-Q and subsequent filings for more information about these risks and uncertainties. With that said, I would like to turn the call over to Christopher. Christopher?

Christopher PeetzChief Executive OfficerSentiment 0.8

Thanks, Andrew, and good afternoon, everyone. At Mirum, we are growing a rare disease leader focused on delivering high-impact medicines for often overlooked diseases. This quarter demonstrates continued progress with strong commercial execution on our approved medicines as we head into the potential launch of our fourth commercial medicine later this year. We have a busy pipeline with multiple pivotal readouts in the quarters ahead, all delivered with strength in capital structure and overall financial performance, giving us greater capacity to invest throughout the business. In the second quarter, our commercial business generated $176 million in net product sales, reflecting strong demand across the portfolio and excellent execution by our team. Based on this performance, we are increasing our full year 2026 net product sales guidance to $680 million to $700 million. Fueled by the strong commercial performance, we are driving towards the next phase of Mirum's growth with multiple milestones over the coming months. Our next commercial …

Leadership Team of MIRM

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Christopher Peetz	Chief Executive Officer & Director	USD 1,826,000	Male	1979	Active
Peter Radovich	Chief Operating Officer & President	USD 1,159,000	Male	1978	Active
Eric H. Bjerkholt	Chief Financial Officer	USD 1,002,000	Male	1960	Active
Joanne J. Quan	Chief Medical Officer	USD 1,002,000	—	1964	Active
Lara Longpre	Chief Development Officer	USD 678,200	Female	1970	Active
Andrew McKibben	Senior Vice President, Strategic Finance & Investor Relations	—	Male	—	Active
Jean-Luc Girardet	Chief Technical Officer	—	—	—	Active
Meredith Kiernan	Senior Director of Global Corporate Communications	—	—	—	Active
Erin Campany	Chief People Officer	—	Female	1968	Active
Douglas T. Sheehy	Chief Legal Officer & Secretary	—	Male	1967	Active

Recent News of MIRM

Business Wire8/11/2026Neutral

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Zacks Investment Research8/6/2026Neutral

Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised

MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

Seeking Alpha8/5/2026Neutral

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript

MarketBeat8/5/2026Neutral

Mirum Pharmaceuticals Q2 Earnings Call Highlights

Mirum Pharmaceuticals NASDAQ: MIRM reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfolios.

Zacks Investment Research8/5/2026Neutral

Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics

The headline numbers for Mirum Pharmaceuticals (MIRM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Historical Employee Count of MIRM

Current

369

Change

+14.60%

Minimum

137

Maximum

369

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	369	10-K	Feb 25, 2026	View
Dec 31, 2024	322	10-K	Feb 26, 2025	View
Dec 31, 2023	264	10-K	Mar 15, 2024	View
Dec 31, 2022	196	10-K	Mar 8, 2023	View
Dec 31, 2021	137	10-K	Mar 9, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Mirum Pharmaceuticals, Inc.